Detailed Information
Cited 9 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt)
- Authors
- Loriot, Y[Loriot, Yohann]; Matsubara, N[Matsubara, Nobuaki]; Park, SH[Park, Se Hoon]; Huddart, RA[Huddart, Robert A.]; Burgess, EF[Burgess, Earle F.]; Houede, N[Houede, Nadine]; Banek, S[Banek, Severine]; Laguerre, B[Laguerre, Brigitte]; Guadalupi, V[Guadalupi, Valentina]; Ku, JH[Ku, Ja Hyeon]; Triantos, S[Triantos, Spyros]; Akapame, S[Akapame, Sydney]; Deprince, K[Deprince, Kris]; Mukhopadhyay, S[Mukhopadhyay, Sutapa]; Siefker-Radtke, AO[Siefker-Radtke, Arlene O.]
- Issue Date
- 10-Jun-2023
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.41, no.17
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 41
- Number
- 17
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.